Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: HTTP request failed! HTTP/1.1 403 Forbidden in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa reviews

besponsa reviews

Перейти к контенту

Главное меню:

besponsa reviews
Welcome to BESPONSA® | BESPONSA®, BESPONSA™ (inotuzumab ozogamicin) | R/R B-Cell ALL , Besponsa - Side Effects, Dosage, Interactions - Drugs , Besponsa Reviews | Everyday Health, Besponsa: Indications, Side Effects, Warnings - Drugs.com, BESPONSA 1 mg powder for concentrate for solution for , , , .
BESPONSA can cause liver problems that can be severe, life-threatening, or fatal, including a condition called veno-occlusive disease (VOD). This condition can occur during treatment with BESPONSA or following subsequent treatment with a stem cell transplant. This condition was more common in patients who had elevated liver tests or who received dual alkylating agents in preparation for their stem cell transplant. Patients may be at a higher risk of VOD if they: . BESPONSA is a prescription medicine used to treat adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). It is not known if BESPONSA is safe and effective in children under 18 years of age.. Learn about the risks & benefits of BESPONSA™, an Rx treatment for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia..
Read Next Besponsa Reviews About Drugs A-Z Drugs A-Z provides drug information from Everyday Health and our partners, as well as ratings from our members, all in one place.. Besponsa received an overall rating of 0 out of 10 stars from 0 reviews. See what others have said about Besponsa, including the effectiveness, ease of use and side effects.. Warning Liver problems have happened with Besponsa (inotuzumab ozogamicin). Sometimes, this has been life-threatening or deadly. The chance of liver problems is higher in people who had a stem cell transplant after treatment with Besponsa (inotuzumab ozogamicin).. There was a trend in favour of BESPONSA for estimated mean postbaseline scores from the EuroQoL 5 Dimension (EQ-5D) questionnaire, (BESPONSA and Investigator's choice of chemotherapy, respectively) for the EQ-5D index (0.80 versus 0.76, minimally important difference for cancer = 0.06).. . .
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню